In a world where most people have limited access to dermatology, BelleTorus Corporation (“Belle.ai”) helps healthcare professionals address the unmet demands for global skin healthcare. From a smartphone photo, Belle 1K Skin AI™ uses geometric analyses to find comparable possibilities for more than 1,600 skin conditions, which assists healthcare professionals in evaluating their patients and independently assessing their skin. Belle.ai’s technology also proposes objective scoring for standard assessments of immune-mediated skin disorders (psoriasis, eczema, alopecia areata, vitiligo) for patients already diagnosed with these conditions to help healthcare professionals track progression over time. Belle.ai’s software is used as a reference tool by providers including Federally Qualified Health Centers, emergency departments and community hospitals. Researchers in low- and middle-income countries around the globe use Belle.ai’s technology to study rare and neglected tropical diseases. Pharmaceutical companies rely on Belle.ai to evaluate their therapeutics through objective image assessment of treatment progression. Belle.ai’s software offerings are not intended to diagnose, treat, cure, or mitigate any disease or condition, and are intended only to assist healthcare professionals in attending to their patients using their independent medical judgment.